Register

Part of the UCSF Helen Diller Family Comprehensive Cancer Center's (HDFCCC) Physician Scientist Program in Clinical Oncology. Talk will be followed by a networking reception from 5:30-6:30pm.

Speakers: Lola Fashoyin-Aje, MD, MPH and Geetika Srivastava MD, MSPH

Lola A. Fashoyin-Aje, MD, MPH, is a medical oncologist and Deputy Division Director in the Division of Oncology 3 (DO3) in the Office of Oncologic Diseases (OOD) at the Food and Drug Administration (FDA). She has served as clinical reviewer in the Gastrointestinal (GI) Malignancies team, and as team leader for the Breast Malignancies, Melanoma and Sarcoma, and Gastrointestinal Malignancies clinical teams. In her current role, she provides scientific and policy guidance and oversight to multidisciplinary teams reviewing drugs and biologics under development for the treatment of solid tumor (GI, sarcoma, melanoma) malignancies. She has also served as the Oncology Center of Excellence (OCE) Scientific Liaison for Cancer Disparities and in this role, has led the OCE’s efforts to improve inclusion of diverse demographic subgroups in clinical trials and participates in several internal and external scientific and policy working groups. Dr. Fashoyin-Aje also serves on the ASCO Health Equity Committee, the AACR Science of Cancer Health Disparities Scientific Program and Scientific Review committees, and the ASCO Cancer Research Committee. Prior to joining the FDA, Dr. Fashoyin-Aje completed her residency in internal medicine and fellowship in medical oncology at Johns Hopkins. She completed her undergraduate and graduate training at Columbia University and Yale University, respectively, and earned her medical degree from the University of Rochester.

Geetika Srivastava MD, MSPH is a hematologist- medical oncologist and a Medical Officer in the Division of Oncology 3 (DO3) in the Office of Oncologic Diseases (OOD) at the Center for Drug Evaluation and Research- Food and Drug Administration (FDA). As a regulatory reviewer she focuses on gastrointestinal (GI) malignancies and is the Vice Chair for FDA committee for GI American Society of Clinical Oncology (ASCO). She is actively involved in Oncology Center of Excellence (OCE) initiatives of Project Endpoint which aims to standardize and enhance use of early endpoint in oncology clinical trials and Project Asiatica, an initiative to bring focus and awareness to Asian American, Native Hawaiian, and Other Pacific Islander (AA & NHPI) patients with cancer. Dr Srivastava treats oncology patients at the Washington DC Veterans Affair Medical Center.

Prior to joining FDA in 2022, Dr Srivastava served as the Oncology Section Chief at Memorial Hospital -University of Colorado in Colorado Springs. Dr Srivastava received her training at All India Institute of Medical Sciences in New Delhi, India, then went on receive Masters in Epidemiology at University of Texas, Houston, TX and worked as a graduate assistant at MD Anderson Cancer Center. She completed her residency training in Internal Medicine at University of Arkansas, Little Rock, AR and Hematology-Medical Oncology fellowship at Mayo Clinic, Rochester, MN.